TSI-01

TSI-01 is a pro-inflammatory phospholipid mediator that is rapidly synthesized by lyso-PAF acetyltransferase (lyso-PAFAT) in response to extracellular stimuli. Two types of lyso-PAFAT have been identified: lysophosphatidylcholine acyltransferase (LPCAT) 1, which is mostly expressed in the lungs, and LPCAT2, which is expressed in inflammatory cells. TSI-01 is a selective inhibitor of LPCAT2 (IC50s=0.47 versus 3.02 μM for human LPCAT2 and LPCAT1, respectively) . 60 μM it is shown to suppress PAF biosynthesis in mouse peritoneal macrophages stimulated with a calcium ionophore.

Product Specifications

CAS Number

[704878-75-1]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Platelet-activating Factor Receptor (PAFR)

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/tsi-01.html

Purity

98.52

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C(C1=CC=C(N2C(C(Cl)=C(C2=O)Cl)=O)C=C1)OC(C)C

Molecular Formula

C14H11Cl2NO4

Molecular Weight

328.15

Precautions

H302, H315, H319, H335

References & Citations

[1]Tarui, et al. Selective inhibitors of a PAF biosynthetic enzyme lysophosphatidylcholine acyltransferase 2. J. Lipid Res. 55 (7), 1386-1396 (2014) .